Polycystic kidney disease (PKD) is a genetic disorder characterized by the development of multiple fluid-filled cysts in the kidneys. The autosomal dominant form (ADPKD) is one of the most common inherited kidney diseases, affecting approximately 1 in 500-1000 people. ADPKD is caused by mutations in PKD1 or PKD2 genes and typically presents in adulthood with progressive renal enlargement, hypertension, and eventual kidney failure. Autosomal recessive PKD (ARPKD) is less common and typically presents in infancy or childhood.
Conditions with similar clinical presentations that must be differentiated from Polycystic Kidney Disease:
Disease Pathophysiology Research Report
Target Disease - Disease Name: Polycystic Kidney Disease (PKD) - MONDO ID: — - Category: Mendelian (autosomal dominant and recessive forms)
Pathophysiology description Polycystic kidney disease is a systemic ciliopathy in which inherited defects in cilia-associated proteins of renal tubular epithelia trigger cyst initiation, clonal expansion, and progressive remodeling of kidney architecture, culminating in chronic kidney disease and end-stage renal disease. In autosomal dominant PKD (ADPKD), loss-of-function mutations in PKD1 (polycystin‑1, PC1) or PKD2 (polycystin‑2, PC2) compromise primary-cilium mechanosensation and calcium flux, elevating cAMP and activating proliferative kinase networks (MAPK/ERK and PI3K–AKT–mTOR). These signals reprogram epithelial metabolism toward glycolysis, drive chloride/water secretion into cyst lumens via CFTR, and promote epithelial‑initiated fibrogenesis and interstitial inflammation that together accelerate cyst growth and nephron loss (https://doi.org/10.3390/genes15010091; https://doi.org/10.3390/ijms25137173) (satariano2024thepathophysiologyof pages 8-10, song2024reprogrammingofenergy pages 1-2). In autosomal recessive PKD (ARPKD), PKHD1 (fibrocystin, FPC) and DZIP1L mutations perturb ciliary/transition-zone function and EGFR/cAMP signaling, producing collecting-duct cysts and hepato-biliary fibrosis; DZIP1L dysfunction also impairs PC1/PC2 ciliary trafficking (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10).
Core Pathophysiology 1) Ciliary dysfunction and mechanotransduction - PC1/PC2 reside at the primary cilium; loss of either reduces intraciliary/cytosolic Ca2+ and disrupts mechanosensory control of downstream growth pathways and polarity cues. Somatic “second hits” are frequent in cyst-lining cells, consistent with a two‑hit model (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - Experimental genetic deletion identifies Aurora kinase A (AURKA) as a feed‑forward driver of cystogenesis via AKT; Aurka deletion prevented cyst formation in Pkd1- and Inpp5e‑driven mouse PKD, linking ciliary control, cell-cycle regulation, and AKT signaling (https://doi.org/10.1038/s41467-023-44410-9; published Jan 2024) (tham2024deletionofaurora pages 1-2).
2) Ca2+/cAMP axis and chloride/fluid secretion - Lowered Ca2+ disinhibits adenylyl cyclases (AC5/6), raising cAMP; PKA then activates B‑Raf–MEK–ERK and PI3K–AKT and enhances CFTR-mediated Cl− secretion that drives osmotic fluid accumulation and cyst expansion (https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2). - Compartmentalized cAMP nanodomains likely exist; a 2024 thesis highlights PDE3 as a regulator of a potentially cyst-protective cAMP pool and suggests PDE3–PC2 interactions at ER–mitochondria contacts, motivating selective modulation beyond V2R blockade (Paolocci 2024; doctoral thesis) (paolocci2024campsignallingand pages 13-17, paolocci2024campsignallingand pages 1-7).
3) Proliferative kinase signaling - cAMP/PKA cooperates with receptor and integrin inputs to activate B‑Raf–MEK–ERK and PI3K–AKT–mTORC1, which promote proliferation and growth programs central to cyst enlargement. AURKA physically interacts with and regulates AKT, completing a loop that sustains cyst growth and ciliary disassembly; pharmacologic AURKA inhibition with alisertib paradoxically stabilized AURKA protein in vivo, cautioning on target modality (https://doi.org/10.1038/s41467-023-44410-9; Jan 2024) (tham2024deletionofaurora pages 1-2).
4) Hippo–YAP/TAZ and RhoA–MRTF fibrosis coupling - Hippo pathway dysregulation in PKD permits nuclear YAP/TAZ and c‑MYC-driven transcription that amplifies proliferative and fibrotic responses (https://doi.org/10.3390/cells13110984; 5 Jun 2024) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - Loss of PC1/PC2 activates RhoA, actin remodeling, and nuclear translocation of myocardin-related transcription factors (MRTF-A/B), which reprogram the cyst epithelium into a profibrotic epithelial phenotype and paracrine-prime fibroblast-to-myofibroblast transition (https://doi.org/10.3390/cells13110984; 2024) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
5) Wnt/planar cell polarity (PCP) - Noncanonical Wnt/PCP defects disturb oriented cell division and tubule architecture, contributing to dilatation and cyst initiation in inherited cystic diseases (https://doi.org/10.3390/genes15010091; 2024) (satariano2024thepathophysiologyof pages 8-10).
6) Metabolic reprogramming and mitochondrial dysfunction - Human PKD1 cyst transcriptomics show Warburg-like shifts: increased glucose uptake and lactate production with broad suppression of FAO, TCA, and OXPHOS; predicted mTORC1/HIF‑1α/MYC activation and AMPK/PGC‑1α suppression provide a regulatory scaffold for these changes (https://doi.org/10.3390/ijms25137173; 26 Jun 2024) (song2024reprogrammingofenergy pages 1-2).
7) Inflammation/immune pathways - Cystic epithelium and interstitium exhibit immune infiltration with cytokine network activation (e.g., IL‑12/23 family; STAT3), contributing to proliferation and fibrosis; STING and TWEAK/Fn14 axes are implicated as amplifiers (review synthesis) (https://doi.org/10.3390/genes15010091; 2024) (satariano2024thepathophysiologyof pages 8-10). - Interstitial fibrosis is further supported by fibroblast–macrophage crosstalk and WNT/β‑catenin signaling in CKD, consistent with profibrotic programs in cystic kidneys (contextualized to PKD) (https://doi.org/10.3390/genes15010091; 2024) (satariano2024thepathophysiologyof pages 8-10).
8) Extracellular matrix remodeling and fibrosis - Epithelial RhoA–MRTF signaling induces ECM/matricellular genes and secreted mediators that remodel the interstitium; epithelial MRTF is necessary for priming myofibroblast differentiation in PKD models (https://doi.org/10.3390/cells13110984; 2024) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
Key Molecular Players Genes/Proteins (HGNC symbol; role) - PKD1 (PC1) and PKD2 (PC2): ciliary mechanosensory complex controlling Ca2+ homeostasis; causal in ADPKD (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - PKHD1 (FPC): ciliary membrane/transition-zone protein; causal in ARPKD; DZIP1L: ciliary trafficking; ARPKD modulator (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - CFTR: apical Cl− channel driving fluid secretion in cysts under cAMP control (https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2). - AURKA: kinase/ciliogenesis regulator forming a feed‑forward loop with AKT driving cystogenesis; genetic deletion prevents cysts in mice (https://doi.org/10.1038/s41467-023-44410-9) (tham2024deletionofaurora pages 1-2). - BRAF–MEK–ERK; PI3K–AKT–mTOR: proliferative/growth pathways activated by cAMP and growth cues (https://doi.org/10.1038/s41467-023-44410-9; https://doi.org/10.3390/ijms25137173) (tham2024deletionofaurora pages 1-2, song2024reprogrammingofenergy pages 1-2). - Hippo effectors YAP1/WWTR1 (TAZ) and RHOA–MRTFA(MKL1)/SRF: proliferation–fibrosis coupling in cyst epithelium (https://doi.org/10.3390/cells13110984) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - STAT3: activated in cystic epithelia and inflammation networks (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - PDE3, AC5/6: cAMP compartmentalization and synthesis/breakdown influencing cystogenesis (Paolocci 2024 thesis) (paolocci2024campsignallingand pages 13-17, paolocci2024campsignallingand pages 1-7).
Chemical entities (CHEBI) - Calcium ion (CHEBI:29108); cAMP (CHEBI:17489); chloride ion (CHEBI:17996); glucose (CHEBI:17234); lactate (CHEBI:24996); vasopressin V2 receptor antagonist tolvaptan (drug; cAMP-lowering in ADPKD) (https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2).
Cell types (CL) - Renal tubular epithelial cells (collecting duct and nephron segments): cyst-lining epithelium (CL term category: epithelial cell) (https://doi.org/10.1038/s41467-023-44410-9; https://doi.org/10.3390/genes15010091) (tham2024deletionofaurora pages 1-2, satariano2024thepathophysiologyof pages 8-10). - Interstitial fibroblasts and myofibroblasts (CL: fibroblast lineage): ECM deposition (https://doi.org/10.3390/cells13110984) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - Macrophages (CL:0000235): inflammatory crosstalk, pro-fibrotic signaling (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10).
Anatomical locations (UBERON) - Kidney (parenchyma); renal tubule and collecting duct (cyst origin); interstitium; liver/biliary tree (ARPKD, polycystic liver disease) (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10).
Biological Processes (GO) disrupted - Cilium organization and ciliary signaling; mechanosensation; calcium ion homeostasis; cAMP signaling; chloride transport; MAPK cascade; PI3K–AKT–mTOR signaling; Hippo signaling; Wnt/PCP pathway; epithelial cell proliferation; epithelial fluid secretion; mitochondrial electron transport and fatty-acid β‑oxidation; extracellular matrix organization; inflammatory response and JAK–STAT cascade (https://doi.org/10.3390/genes15010091; https://doi.org/10.3390/ijms25137173; https://doi.org/10.3390/cells13110984; https://doi.org/10.1038/s41467-023-44410-9) (satariano2024thepathophysiologyof pages 8-10, song2024reprogrammingofenergy pages 1-2, lichner2024myocardinrelatedtranscriptionfactor pages 1-2, tham2024deletionofaurora pages 1-2).
Cellular Components (GO-CC) - Primary cilium, ciliary membrane, basal body; apical plasma membrane (CFTR); endoplasmic reticulum and mitochondrion (Ca2+ exchange and metabolism); extracellular region/extracellular matrix (https://doi.org/10.3390/genes15010091; https://doi.org/10.3390/ijms25137173) (satariano2024thepathophysiologyof pages 8-10, song2024reprogrammingofenergy pages 1-2).
Disease Progression (sequence of events) - Genetic lesion and second hit: germline PKD1/PKD2 (ADPKD) or PKHD1/DZIP1L (ARPKD) mutations with somatic inactivation in individual tubular cells initiate cysts (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - Cyst initiation: ciliary Ca2+ signaling failure increases cAMP; polarity/PCP cues are disturbed; early luminal fluid accumulation occurs via CFTR-mediated Cl− secretion (https://doi.org/10.3390/ijms25137173; https://doi.org/10.3390/genes15010091) (song2024reprogrammingofenergy pages 1-2, satariano2024thepathophysiologyof pages 8-10). - Cyst expansion: PKA–ERK and AKT–mTORC1 drive epithelial proliferation and growth; metabolic reprogramming supports biomass and energy; AURKA–AKT feed‑forward loop and Hippo/YAP amplify proliferation; RhoA–MRTF primes fibrosis (https://doi.org/10.1038/s41467-023-44410-9; https://doi.org/10.3390/ijms25137173; https://doi.org/10.3390/cells13110984) (tham2024deletionofaurora pages 1-2, song2024reprogrammingofenergy pages 1-2, lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - Tissue remodeling: interstitial inflammation and fibroblast activation produce fibrosis; nephron dropout and vascular rarefaction ensue, causing progressive GFR decline (https://doi.org/10.3390/genes15010091; https://doi.org/10.3390/cells13110984) (satariano2024thepathophysiologyof pages 8-10, lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - ARPKD distinctions: collecting-duct–predominant cysts with congenital hepatic fibrosis; fibrocystin C-terminal signaling restrains Src/STAT3 and secretory phenotypes in model systems, consistent with heightened STAT3 signaling when FPC is deficient (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10).
Phenotypic Manifestations (HP terms) - Renal cysts (HP:0000107), Enlarged kidneys (HP:0000105), Hypertension (HP:0000822), Hematuria (HP:0000790), Flank/abdominal pain; Hepatic cysts (HP:0001407) and congenital hepatic fibrosis (ARPKD); Intracranial aneurysm risk (HP:0002617). These manifestations reflect tubular cyst burden, interstitial fibrosis/inflammation, and systemic vascular/ductal involvement (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10).
Recent developments and latest research (2023–2024 priority) - AURKA–AKT feed‑forward loop as a master regulator: Aurka deletion prevented PKD across two genetic models; the data highlight non-kinase functions and caution that alisertib can stabilize AURKA in vivo, informing drug design (Nature Communications, 10 Jan 2024; https://doi.org/10.1038/s41467-023-44410-9) (tham2024deletionofaurora pages 1-2). - Human PKD1 cyst metabolic atlas: Systems biology analysis mapped a Warburg shift with predicted mTORC1/HIF‑1α/MYC activation and suppressed AMPK/PGC‑1α, concretizing metabolism-targeted therapies (IJMS, 26 Jun 2024; https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2). - Epithelial-initiated fibrogenesis: PKD epithelium activates RhoA–MRTF programs that prime myofibroblast transition, providing epithelial targets for anti-fibrotic intervention (Cells, 5 Jun 2024; https://doi.org/10.3390/cells13110984) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - ARPKD gene and pathway synthesis: Updated review integrates PKHD1/DZIP1L ciliary biology with EGFR/cAMP and ECM remodeling, clarifying pediatric hepato-renal disease mechanisms (Genes, 5 Jan 2024; https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - cAMP compartmentalization: New experimental work proposes PDE3 as a modulator of organelle cAMP nanodomains and potential PC2 interactor at ER–mitochondrial contacts (doctoral thesis, 2024) (paolocci2024campsignallingand pages 13-17, paolocci2024campsignallingand pages 1-7).
Current applications and implementations - Disease-modifying therapy: Tolvaptan (V2R antagonist) is approved to slow ADPKD progression by reducing cAMP; translational metabolism strategies (e.g., ketogenic interventions, AMPK activation) are supported by the human cyst metabolic signatures but require rigorous trials (https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2). - Emerging targets: AURKA–AKT axis, RhoA–MRTF signaling, Hippo/YAP, and cytokine–STAT3 pathways represent testable targets; the in vivo genetic validation of AURKA strengthens prioritization (https://doi.org/10.1038/s41467-023-44410-9; https://doi.org/10.3390/cells13110984) (tham2024deletionofaurora pages 1-2, lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
Expert opinions and analysis - 2024 syntheses argue that PKD integrates ciliary signaling failure with proliferative and metabolic rewiring; epithelial cells both initiate cystogenesis and act as paracrine organizers of interstitial fibrosis, implying dual-acting therapies that combine cAMP reduction, proliferation blockade, and anti-fibrotic reprogramming may be required for durable benefit (https://doi.org/10.3390/ijms25137173; https://doi.org/10.3390/cells13110984; https://doi.org/10.3390/genes15010091) (song2024reprogrammingofenergy pages 1-2, lichner2024myocardinrelatedtranscriptionfactor pages 1-2, satariano2024thepathophysiologyof pages 8-10).
Relevant statistics and data from recent studies - Genetic architecture: ADPKD due to PKD1 (~75–85%) or PKD2 (~15–25%); ARPKD due to PKHD1 with DZIP1L as a rarer cause/modifier (2024 review synthesis) (https://doi.org/10.3390/genes15010091) (satariano2024thepathophysiologyof pages 8-10). - Metabolic pathways: In human PKD1 cysts, gene sets for FAO, OXPHOS, BCAA degradation, and TCA cycle were downregulated, while glycolysis and lactate transporters were upregulated, aligning with predicted mTORC1/HIF‑1α/MYC activation and AMPK inhibition (IJMS 2024) (https://doi.org/10.3390/ijms25137173) (song2024reprogrammingofenergy pages 1-2). - In vivo mechanistic validation: Aurka deletion blocked cyst initiation and growth in two independent mouse PKD models and revealed AKT–AURKA physical interaction and a feed‑forward loop (Nature Communications 2024) (https://doi.org/10.1038/s41467-023-44410-9) (tham2024deletionofaurora pages 1-2).
Gene/protein annotations with ontology terms - HGNC: PKD1, PKD2, PKHD1, DZIP1L, CFTR, AURKA, BRAF, MAP2K1 (MEK1), MAPK1 (ERK2), PIK3CA, AKT1, MTOR, YAP1, WWTR1 (TAZ), RHOA, MRTFA (MKL1), SRF, STAT3, ADCY5/6, PDE3A/B (tham2024deletionofaurora pages 1-2, song2024reprogrammingofenergy pages 1-2, satariano2024thepathophysiologyof pages 8-10, lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - GO BP: cilium organization; calcium ion homeostasis; cAMP signaling; chloride transport; MAPK cascade; PI3K–AKT signaling; mTOR signaling; Hippo signaling; Wnt/PCP; epithelial cell proliferation; epithelial fluid secretion; mitochondrial electron transport chain; fatty acid β-oxidation; extracellular matrix organization; inflammatory response; JAK–STAT cascade (tham2024deletionofaurora pages 1-2, song2024reprogrammingofenergy pages 1-2, satariano2024thepathophysiologyof pages 8-10, lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - GO CC: primary cilium; ciliary membrane; basal body; apical plasma membrane; endoplasmic reticulum; mitochondrion; extracellular matrix (song2024reprogrammingofenergy pages 1-2, satariano2024thepathophysiologyof pages 8-10).
Phenotype associations (HP terms) - Renal cysts (HP:0000107); Enlarged kidneys (HP:0000105); Hypertension (HP:0000822); Hematuria (HP:0000790); Hepatic cysts (HP:0001407); Intracranial aneurysm (HP:0002617) (satariano2024thepathophysiologyof pages 8-10).
Cell type involvement (CL terms) - Renal tubular epithelial cell (cyst-lining); fibroblast/myofibroblast; macrophage (tham2024deletionofaurora pages 1-2, satariano2024thepathophysiologyof pages 8-10, lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
Anatomical locations (UBERON terms) - Kidney; renal tubule; collecting duct; renal interstitium; liver/biliary tree (satariano2024thepathophysiologyof pages 8-10).
Chemical entities (CHEBI) - Calcium ion; cAMP; chloride ion; glucose; lactate; tolvaptan (drug) (song2024reprogrammingofenergy pages 1-2).
Evidence items (PMIDs/DOIs and dates) - Tham et al., Nature Communications, 10 Jan 2024. “Deletion of Aurora kinase A prevents the development of polycystic kidney disease in mice.” https://doi.org/10.1038/s41467-023-44410-9 (tham2024deletionofaurora pages 1-2). - Song et al., International Journal of Molecular Sciences, 26 Jun 2024. “Reprogramming of Energy Metabolism in Human PKD1 Polycystic Kidney Disease.” https://doi.org/10.3390/ijms25137173 (song2024reprogrammingofenergy pages 1-2). - Lichner et al., Cells, 5 Jun 2024. “Myocardin-Related Transcription Factor Mediates Epithelial Fibrogenesis in PKD.” https://doi.org/10.3390/cells13110984 (lichner2024myocardinrelatedtranscriptionfactor pages 1-2). - Satariano et al., Genes, 5 Jan 2024. “The Pathophysiology of Inherited Renal Cystic Diseases.” https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10). - Paolocci E., 2024 thesis. “cAMP signalling and phosphodiesterase activity in cystogenesis of ADPKD.” (paolocci2024campsignallingand pages 13-17, paolocci2024campsignallingand pages 1-7).
Summary artifact | Mechanistic domain | Key findings (1–2 sentences) | Principal molecules/genes | Cell types | 2023–2024 sources (journal, year, URL/DOI) | |---|---|---|---|---| | Ciliary dysfunction & mechanotransduction | Loss or dysfunction of PC1/PC2 in primary cilia impairs ciliary Ca2+ mechanosensing, disrupting downstream signaling and promoting cyst initiation; somatic "second hits" in cysts are common. | PKD1 (PC1), PKD2 (PC2), IFT/KIF genes | Renal tubular epithelial cells (collecting duct, nephron epithelia) | Nature Communications, 2024, https://doi.org/10.1038/s41467-023-44410-9 (tham2024deletionofaurora pages 1-2); Genes, 2024, https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10) | | Ca2+/cAMP and CFTR-mediated Cl- secretion | Reduced intraciliary/cytosolic Ca2+ disinhibits adenylyl cyclases increasing cAMP; cAMP/PKA promotes epithelial proliferation and CFTR-mediated chloride/fluid secretion that expands cysts; V2R antagonism (tolvaptan) lowers cAMP clinically. | AC5/6, cAMP, PDE3, CFTR, AVPR2 (V2R) | Cyst-lining epithelial cells | Unknown journal, 2024 (Paolocci thesis) (paolocci2024campsignallingand pages 13-17); IJMS, 2024, https://doi.org/10.3390/ijms25137173 (song2024reprogrammingofenergy pages 1-2) | | Proliferative signaling (MAPK/ERK, PI3K/AKT/mTOR) | cAMP/PKA and growth-receptor signaling activate B-Raf→MEK→ERK and PI3K→AKT→mTORC1, driving cell cycle entry, growth and metabolic programs that sustain cyst growth. | BRAF/MEK/ERK, PI3K, AKT, mTOR, c-MYC | Tubular epithelial cells (cyst epithelium) | Nature Communications, 2024, https://doi.org/10.1038/s41467-023-44410-9 (tham2024deletionofaurora pages 1-2); IJMS, 2024, https://doi.org/10.3390/ijms25137173 (song2024reprogrammingofenergy pages 1-2) | | Hippo — YAP/TAZ | Dysregulated Hippo signaling permits nuclear YAP/TAZ activity, promoting transcriptional programs (e.g., c-MYC) that increase proliferation and link to fibrogenic responses. | YAP, TAZ, LATS1/2, MST1/2 | Cyst-lining epithelial cells; epithelial progenitors | Cells, 2024, https://doi.org/10.3390/cells13110984 (lichner2024myocardinrelatedtranscriptionfactor pages 1-2); Genes, 2024, https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10) | | Wnt / Planar cell polarity (PCP) | Defects in Wnt/PCP signaling disrupt oriented cell division and tubule architecture, contributing to abnormal tubule dilation and cyst formation. | WNT ligands, VANGL/CELSR, DVL | Tubular epithelial cells | Genes, 2024, https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10) | | Metabolic reprogramming & mitochondria | Cystic epithelia show a Warburg-like shift (↑glycolysis, ↑lactate) with suppressed FAO and OXPHOS, AMPK inhibition and mTOR activation, supporting proliferation and survival. | GLUTs, HK1/2, LDHA, PDK1, AMPK, PGC‑1α | Cyst-lining epithelial cells | IJMS, 2024, https://doi.org/10.3390/ijms25137173 (song2024reprogrammingofenergy pages 1-2) | | Inflammation & immune (JAK/STAT, cytokines) | Immune cell infiltration and cytokine dysregulation (e.g., IL‑family) activate JAK/STAT and NF‑κB pathways, amplifying epithelial proliferation and fibrotic remodeling. | IL family (IL‑12/23), JAK/STAT3, NF‑κB, STING, TWEAK/Fn14 | Macrophages, epithelial cells, fibroblasts | Genes, 2024, https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10); Cells, 2024, https://doi.org/10.3390/cells13110984 (lichner2024myocardinrelatedtranscriptionfactor pages 1-2) | | ECM remodeling & fibrosis (MRTF; fibroblast–macrophage crosstalk) | Epithelial RhoA activation drives MRTF nuclear translocation and profibrotic gene expression, priming fibroblast→myofibroblast transition; reciprocal Wnt–macrophage–fibroblast crosstalk promotes interstitial fibrosis. | RHOA, MRTF‑A/B, SRF, collagen, TGF‑β, WNT | Tubular epithelial cells, interstitial fibroblasts, macrophages | Cells, 2024, https://doi.org/10.3390/cells13110984 (lichner2024myocardinrelatedtranscriptionfactor pages 1-2); Genes, 2024, https://doi.org/10.3390/genes15010091 (satariano2024thepathophysiologyof pages 8-10) | | Cell cycle / ciliogenesis regulators (AURKA) | AURKA is upregulated in PKD, promotes proliferation and ciliary disassembly and forms a feed‑forward loop with AKT; genetic deletion of Aurka prevents cyst formation in mouse PKD models. | AURKA, AKT | Collecting-duct and tubular epithelial cells | Nature Communications, 2024, https://doi.org/10.1038/s41467-023-44410-9 (tham2024deletionofaurora pages 1-2) |
Table: Compact 2023–2024 evidence map summarizing major molecular/cellular mechanisms in ADPKD/ARPKD, with principal genes, affected cell types, and primary sources; useful as a quick reference linking mechanisms to recent literature (context citations included).
Direct quotes supporting key statements - “Deletion of the Aurora Kinase A gene… prevents cyst formation in both disease models… AURKA and AKT physically interact… creating a feed-forward loop driving renal cystogenesis.” (Nature Communications, 2024) (tham2024deletionofaurora pages 1-2). - “Gene expression profiles of PKD1 renal cysts were consistent with the Warburg effect… mitochondrial energy metabolism was globally depressed… activation of mTORC1 and… HIF-1α and MYC… AMPK inhibition was predicted in renal cysts.” (IJMS, 2024) (song2024reprogrammingofenergy pages 1-2). - “The loss of PC1 or PC2… activated RhoA… robust nuclear MRTF translocation… epithelial MRTF was necessary for the paracrine priming of the fibroblast–myofibroblast transition.” (Cells, 2024) (lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
Conclusion PKD pathogenesis is best understood as an integrated network linking primary-cilium dysfunction and Ca2+/cAMP derangements to proliferative signaling, metabolic reprogramming, and fibrotic/inflammatory remodeling. Recent 2024 studies provide in vivo mechanistic validation (AURKA–AKT) and human cyst metabolic maps (Warburg shift), while epithelial RhoA–MRTF signaling emerges as a nexus between cystogenesis and fibrosis. These insights nominate combined strategies—precise cAMP modulation, anti-proliferative pathway inhibition, and anti-fibrotic reprogramming—as rational avenues to slow disease progression beyond current V2R antagonism (https://doi.org/10.1038/s41467-023-44410-9; https://doi.org/10.3390/ijms25137173; https://doi.org/10.3390/cells13110984) (tham2024deletionofaurora pages 1-2, song2024reprogrammingofenergy pages 1-2, lichner2024myocardinrelatedtranscriptionfactor pages 1-2).
References
(satariano2024thepathophysiologyof pages 8-10): Matthew Satariano, Shaarav Ghose, and Rupesh Raina. The pathophysiology of inherited renal cystic diseases. Genes, 15:91, Jan 2024. URL: https://doi.org/10.3390/genes15010091, doi:10.3390/genes15010091. This article has 9 citations and is from a poor quality or predatory journal.
(song2024reprogrammingofenergy pages 1-2): Xuewen Song, Lauren Pickel, Hoon-Ki Sung, James W. Scholey, and York Pei. Reprogramming of energy metabolism in human pkd1 polycystic kidney disease: a systems biology analysis. International Journal of Molecular Sciences, 25:7173, Jun 2024. URL: https://doi.org/10.3390/ijms25137173, doi:10.3390/ijms25137173. This article has 8 citations and is from a poor quality or predatory journal.
(tham2024deletionofaurora pages 1-2): Ming Shen Tham, Denny L. Cottle, Allara K. Zylberberg, Kieran M. Short, Lynelle K. Jones, Perkin Chan, Sarah E. Conduit, Jennifer M. Dyson, Christina A. Mitchell, and Ian M. Smyth. Deletion of aurora kinase a prevents the development of polycystic kidney disease in mice. Nature Communications, Jan 2024. URL: https://doi.org/10.1038/s41467-023-44410-9, doi:10.1038/s41467-023-44410-9. This article has 15 citations and is from a highest quality peer-reviewed journal.
(paolocci2024campsignallingand pages 13-17): E Paolocci. Camp signalling and phosphodiesterase activity in cystogenesis of autosomal dominant polycystic kidney disease. Unknown journal, 2024.
(paolocci2024campsignallingand pages 1-7): E Paolocci. Camp signalling and phosphodiesterase activity in cystogenesis of autosomal dominant polycystic kidney disease. Unknown journal, 2024.
(lichner2024myocardinrelatedtranscriptionfactor pages 1-2): Zsuzsanna Lichner, Mei Ding, Tarang Khare, Qinghong Dan, Raquel Benitez, Mercédesz Praszner, Xuewen Song, Rola Saleeb, Boris Hinz, York Pei, Katalin Szászi, and András Kapus. Myocardin-related transcription factor mediates epithelial fibrogenesis in polycystic kidney disease. Cells, 13:984, Jun 2024. URL: https://doi.org/10.3390/cells13110984, doi:10.3390/cells13110984. This article has 4 citations and is from a poor quality or predatory journal.
name: Polycystic Kidney Disease
creation_date: '2026-01-09T06:06:08Z'
updated_date: '2026-03-31T04:24:07Z'
category: Mendelian
description: >
Polycystic kidney disease (PKD) is a genetic disorder characterized by the
development of multiple fluid-filled cysts in the kidneys. The autosomal dominant
form (ADPKD) is one of the most common inherited kidney diseases, affecting
approximately 1 in 500-1000 people. ADPKD is caused by mutations in PKD1 or PKD2
genes and typically presents in adulthood with progressive renal enlargement,
hypertension, and eventual kidney failure. Autosomal recessive PKD (ARPKD) is
less common and typically presents in infancy or childhood.
disease_term:
preferred_term: polycystic kidney disease
term:
id: MONDO:0020642
label: polycystic kidney disease
parents:
- Genetic Kidney Disease
- Ciliopathy
has_subtypes:
- name: Autosomal Dominant PKD (ADPKD)
description: Most common form, caused by PKD1 or PKD2 mutations, typically presenting in adulthood.
- name: Autosomal Recessive PKD (ARPKD)
description: Less common form caused by PKHD1 mutations, presenting in infancy or childhood with more severe phenotype.
prevalence:
- population: United States ADPKD populations
percentage: 9.3 per 10,000
notes: >-
The clinically recognized prevalence of polycystic kidney disease is driven
predominantly by ADPKD, the common adult-onset subtype.
evidence:
- reference: PMID:40126492
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "ADPKD accounts for 5% to 10% of kidney failure in the US and Europe, and its prevalence in the US is 9.3 per 10 000 individuals."
explanation: This recent review gives a contemporary clinically recognized prevalence estimate for ADPKD, which constitutes most PKD cases.
- reference: PMID:24162855
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autosomal dominant polycystic kidney disease (ADPKD) is the most common form of polycystic kidney disease with an incidence of 1 in 800 live births."
explanation: This review-level epidemiology supports the high birth incidence of ADPKD within the broader PKD category.
- population: Global ARPKD live births
percentage: 1 in 20,000 live births
notes: >-
ARPKD is much rarer than ADPKD and mainly accounts for the infantile and
childhood end of the PKD spectrum.
evidence:
- reference: PMID:24162855
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Autosomal recessive polycystic kidney disease (ARPKD) is the recessive form of PKD that has an incidence of 1 in 20 000 and is associated with perinatal and early infantile death."
explanation: This review directly states the incidence for the recessive PKD subtype.
pathophysiology:
- name: Vasopressin/cAMP-Driven Cyst Expansion
description: >
Elevated vasopressin signaling via V2 receptors increases cAMP in tubular
epithelial cells, driving chloride and fluid secretion into cysts and promoting
cyst wall growth. Blocking V2 signaling slows total kidney volume expansion.
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
explanation: Tolvaptan’s effect on kidney volume underscores vasopressin/cAMP signaling as a key driver of cyst expansion.
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
biological_processes:
- preferred_term: cAMP/PKA signal transduction
term:
id: GO:0141156
label: cAMP/PKA signal transduction
- name: Epithelial Proliferation and Kidney Enlargement
description: >
Reduced polycystin-mediated restraint on epithelial proliferation leads to
progressive cyst wall growth and parenchymal compression, increasing total
kidney volume and reducing renal function.
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "slowed the growth in total kidney volume and the decline in the estimated glomerular filtration rate"
explanation: Dampening kidney volume growth parallels slower GFR loss, linking cyst epithelial proliferation to functional decline.
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
biological_processes:
- preferred_term: regulation of cell proliferation
term:
id: GO:0042127
label: regulation of cell population proliferation
- name: Ciliary Dysfunction
description: >
Primary cilia act as mechanosensors in renal tubular epithelial cells.
Polycystin dysfunction impairs ciliary signaling, disrupting normal tubular
architecture and promoting cyst formation through increased cAMP signaling.
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
explanation: Reduction of cyst growth via V2 receptor blockade underscores cAMP-mediated ciliary signaling as a driver of cystogenesis.
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
biological_processes:
- preferred_term: cilium organization
term:
id: GO:0044782
label: cilium organization
- preferred_term: cAMP/PKA signal transduction
term:
id: GO:0141156
label: cAMP/PKA signal transduction
- name: Fibrosis and Inflammation
description: >
Progressive cyst growth triggers interstitial inflammation and fibrosis.
Activated myofibroblasts deposit extracellular matrix, contributing to
nephron loss and declining kidney function.
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "ADPKD accounts for 5% to 10% of kidney failure in the US and Europe"
explanation: High kidney failure burden reflects cumulative nephron loss from cyst-driven injury and interstitial fibrosis.
cell_types:
- preferred_term: macrophage
term:
id: CL:0000235
label: macrophage
biological_processes:
- preferred_term: inflammatory response
term:
id: GO:0006954
label: inflammatory response
phenotypes:
- name: Multiple Renal Cysts
category: Renal
frequency: VERY_FREQUENT
description: Multiple fluid-filled cysts in both kidneys, progressively enlarging over time.
phenotype_term:
preferred_term: Multiple renal cysts
term:
id: HP:0005562
label: Multiple renal cysts
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
explanation: REPRISE trial confirms PKD as a cystic kidney disease defined by progressive kidney volume increase.
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Autosomal dominant polycystic kidney disease (ADPKD) is characterized by progressive development of kidney cysts"
explanation: JAMA review describes ADPKD as a progressive cystic kidney disease.
- name: Hypertension
category: Cardiovascular
frequency: VERY_FREQUENT
description: High blood pressure, often preceding decline in renal function.
phenotype_term:
preferred_term: Hypertension
term:
id: HP:0000822
label: Hypertension
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Hypertension affects 70% to 80% of patients with ADPKD"
explanation: "JAMA review confirms very high prevalence of hypertension in ADPKD patients."
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Optimal management of ADPKD includes systolic blood pressure lower than 120 mm Hg for most patients"
explanation: Tight blood pressure targets underscore hypertension as a central clinical issue in ADPKD.
- reference: PMID:40371605
reference_title: "Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients."
supports: SUPPORT
snippet: "Comorbidities include hypertension, flank pain, and bacterial infections."
explanation: Proteomic study lists hypertension as a common comorbidity in ADPKD cohorts.
- name: Chronic Kidney Disease
category: Renal
frequency: VERY_FREQUENT
description: Progressive decline in kidney function, with approximately 50% reaching end-stage renal disease by age 60.
phenotype_term:
preferred_term: Chronic kidney disease
term:
id: HP:0012622
label: Chronic kidney disease
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m2"
explanation: Trial demonstrates progressive GFR decline in PKD patients.
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age"
explanation: High rate of kidney replacement therapy highlights progression to advanced CKD in ADPKD.
- name: Hepatic Cysts
category: Hepatic
frequency: FREQUENT
description: Liver cysts are common extrarenal manifestation, more prevalent in women.
phenotype_term:
preferred_term: Hepatic cysts
term:
id: HP:0001407
label: Hepatic cysts
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "More than 90% of patients older than 35 years have hepatic cysts"
explanation: "JAMA review confirms hepatic cysts as a very common manifestation in ADPKD."
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "More than 90% of patients older than 35 years have hepatic cysts, which may cause abdominal discomfort and occasionally require medical or surgical intervention"
explanation: Describes prevalence plus symptomatic burden and intervention needs from hepatic cysts in ADPKD.
- name: Intracranial Aneurysm
category: Vascular
frequency: OCCASIONAL
description: Cerebral berry aneurysms occur in 5-10% of ADPKD patients, with risk of rupture.
phenotype_term:
preferred_term: Cerebral berry aneurysm
term:
id: HP:0007029
label: Cerebral berry aneurysm
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "approximately 9% to 14% develop intracranial aneurysms"
explanation: "JAMA review confirms intracranial aneurysms occur in 9-14% of ADPKD patients."
- name: Flank Pain
category: Renal
frequency: FREQUENT
description: Chronic or acute pain due to cyst hemorrhage, infection, or mass effect.
phenotype_term:
preferred_term: Flank pain
term:
id: HP:0030157
label: Flank pain
evidence:
- reference: PMID:40371605
reference_title: "Changes in Protein Expression of Renal Drug Transporters and Drug-Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients."
supports: SUPPORT
snippet: "Comorbidities include hypertension, flank pain, and bacterial infections."
explanation: Proteomic study notes flank pain as a common comorbidity in ADPKD patients.
biochemical:
- name: Elevated Creatinine
presence: Elevated
context: Marker of declining renal function in advanced disease
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "The change from baseline in the estimated GFR was -2.34 ml per minute per 1.73 m2"
explanation: Progressive GFR decline reflects rising creatinine as renal function deteriorates.
- name: Decreased GFR
presence: Decreased
context: Progressive decline reflecting nephron loss
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "as compared with -3.61 ml per minute per 1.73 m2 (95% CI, -4.08 to -3.14) in the placebo group"
explanation: Trial quantifies ongoing GFR loss in ADPKD absent disease-modifying therapy.
genetic:
- name: PKD1 Mutations
association: Causative
notes: Accounts for approximately 85% of ADPKD cases; encodes polycystin-1; typically more severe phenotype with earlier onset of ESRD
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."
explanation: JAMA review quantifies PKD1 as the predominant cause of ADPKD.
- name: PKD2 Mutations
association: Causative
notes: Accounts for approximately 15% of ADPKD cases; encodes polycystin-2; milder phenotype with later onset of ESRD
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "ADPKD is typically diagnosed in individuals aged 27 to 42 years and is primarily caused by pathogenic variants in the PKD1 (78%) or PKD2 (15%) genes."
explanation: JAMA review documents PKD2 as a minority but established cause of ADPKD.
- name: PKHD1 Mutations
association: Causative
notes: Causes autosomal recessive PKD; encodes fibrocystin/polyductin
evidence:
- reference: PMID:41467628
reference_title: "Clinical characteristics and genotype-phenotype correlation for patients with autosomal recessive polycystic kidney disease and PKHD1 mutations."
supports: SUPPORT
snippet: "Autosomal recessive polycystic kidney disease (ARPKD) is a rare disorder mainly caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene."
explanation: Clin Nephrol study states PKHD1 mutations as the primary cause of ARPKD.
environmental:
- name: Caffeine Consumption
notes: May accelerate cyst growth through increased cAMP levels; patients often advised to limit intake
evidence:
- reference: PMID:20301424
reference_title: "Polycystic Kidney Disease, Autosomal Dominant."
supports: SUPPORT
snippet: "Agents/circumstances to avoid: ... high levels of caffeine"
explanation: GeneReviews lists high caffeine intake as an avoidable factor in ADPKD management.
treatments:
- name: Tolvaptan
description: >
Vasopressin V2 receptor antagonist that slows cyst growth and kidney
enlargement in ADPKD. First disease-modifying therapy approved for ADPKD.
Requires hepatic monitoring due to risk of elevated liver enzymes.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
therapeutic_agent:
- preferred_term: tolvaptan
term:
id: CHEBI:32246
label: tolvaptan
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD."
explanation: REPRISE trial demonstrated tolvaptan efficacy in slowing GFR decline in PKD patients.
- name: Blood Pressure Control
description: >
Aggressive hypertension management with ACE inhibitors or ARBs to slow
disease progression and reduce cardiovascular risk.
treatment_term:
preferred_term: pharmacotherapy
term:
id: MAXO:0000058
label: pharmacotherapy
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "First-line treatment includes blood pressure control, dietary and weight management, and adequate hydration."
explanation: "JAMA review confirms blood pressure control as first-line treatment for ADPKD."
- name: Renal Dialysis
description: >
Dialysis (hemodialysis or peritoneal dialysis) for end-stage renal disease.
PKD is one of the leading causes of kidney failure requiring dialysis.
treatment_term:
preferred_term: renal dialysis
term:
id: MAXO:0000601
label: renal dialysis
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."
explanation: "JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."
- name: Kidney Transplantation
description: >
Kidney transplantation is the preferred treatment for end-stage renal disease
in PKD. Native nephrectomy may be required if kidneys are too large.
treatment_term:
preferred_term: organ transplantation
term:
id: MAXO:0010039
label: organ transplantation
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Approximately 50% of individuals with ADPKD require kidney replacement therapy by 62 years of age."
explanation: "JAMA review confirms high rate of kidney replacement therapy (dialysis/transplant) in ADPKD."
differential_diagnoses:
- name: Simple Renal Cysts (Age-Related)
disease_term:
preferred_term: simple renal cyst
term:
id: MONDO:0004840
label: non-congenital cyst of kidney
description: >
Solitary or few benign cysts that enlarge slowly with age and lack family history
or extrarenal cysts. ADPKD shows bilateral numerous cysts with progressive total
kidney volume growth.
distinguishing_features:
- Typically solitary or few cysts without kidney enlargement
- No hepatic cysts or family history of cystic disease
- Stable kidney function and volume over time
evidence:
- reference: PMID:29105594
reference_title: "Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease."
supports: SUPPORT
snippet: "the vasopressin V2-receptor antagonist tolvaptan slowed the growth in total kidney volume"
explanation: Progressive total kidney volume growth distinguishes ADPKD from stable simple cysts.
- name: Acquired Cystic Kidney Disease (ACKD)
disease_term:
preferred_term: acquired cystic kidney disease
term:
id: MONDO:0002473
label: cystic kidney disease
description: >
Cystic change that develops in chronically dialyzed kidneys, usually in the
setting of long-standing kidney failure. Kidneys are often small or normal size
rather than massively enlarged as in ADPKD.
distinguishing_features:
- Occurs after years of dialysis or advanced CKD without family history
- Kidneys remain small/normal sized rather than enlarged
- Lacks extensive hepatic cysts common in ADPKD
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "Patients with MIC 1C to MIC 1E have larger kidneys because of more rapid growth (6%-10% per year)"
explanation: Rapid kidney enlargement in ADPKD contrasts with small kidneys seen in ACKD.
- name: Tuberous Sclerosis Complex (TSC)
disease_term:
preferred_term: tuberous sclerosis
term:
id: MONDO:0001734
label: tuberous sclerosis
description: >
Genetic disorder with renal cysts and angiomyolipomas that can mimic ADPKD but
accompanied by dermatologic and neurologic manifestations.
distinguishing_features:
- Renal angiomyolipomas and cortical tubers with seizures or developmental issues
- Cutaneous findings (facial angiofibromas, hypomelanotic macules) absent in ADPKD
- ADPKD frequently shows extensive hepatic cysts, which are uncommon in TSC
evidence:
- reference: PMID:40126492
reference_title: "Autosomal Dominant Polycystic Kidney Disease: A Review."
supports: SUPPORT
snippet: "More than 90% of patients older than 35 years have hepatic cysts"
explanation: High hepatic cyst burden supports ADPKD over TSC when liver cysts dominate.
experimental_models:
- name: ADPKD kidney organoid cystogenesis model
description: >-
Human kidney organoids derived from patient-specific or gene-edited induced
pluripotent stem cells model early ADPKD cyst initiation in a genetically
relevant renal epithelial context and support preclinical compound testing.
experimental_model_type: ORGANOID
namo_type: namo:Organoid
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
tissue_term:
preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
conditions:
- autosomal dominant polycystic kidney disease
- PKD1 heterozygous mutation
- patient-derived hiPSC
- gene-edited hiPSC
- healthy control
cell_source: Disease-specific or gene-edited human induced pluripotent stem cells differentiated into kidney organoids
culture_system: Three-dimensional kidney organoid culture with differentiated renal epithelial cyst readouts
publication: PMID:32819584
findings:
- statement: ADPKD kidney organoids reproduce renal cyst formation from genetically relevant human renal epithelium
evidence:
- reference: PMID:32819584
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Importantly, we found that kidney organoids differentiated from gene-edited heterozygous PKD1-mutant as well as ADPKD patient-derived hiPSCs can reproduce renal cysts."
explanation: Shows that both engineered and patient-derived human iPSC kidney organoids recapitulate the core cystic phenotype of ADPKD.
- statement: Tubular epithelial organoids also capture early PKD1-linked morphogenesis and ciliary defects relevant to cyst initiation
evidence:
- reference: PMID:40140667
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "PKD1 null (PKD1-/-) organoids spontaneously develop dilated tubules, recapitulating early ADPKD cystogenesis. Furthermore, PKD1-/- tubules present primary cilia defects when dilated."
explanation: Supports a restrained mechanistic link between human organoid phenotypes and the ciliary and tubular morphogenesis abnormalities represented in PKD pathophysiology.
evidence:
- reference: PMID:32819584
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Here, we report a novel ADPKD model using kidney organoids derived from disease-specific human induced pluripotent stem cells (hiPSCs)."
explanation: Supports this as a first-class human organoid model for ADPKD.
notes: >-
Most informative for early epithelial and ciliary mechanisms of cyst
initiation rather than late interstitial remodeling.
- name: Adult ADPKD kidney tubuloid model
description: >-
Adult kidney tubuloids expanded from CD24-positive tubular epithelial cells
provide a long-term human epithelial model of ADPKD that preserves adult
tubular identity and supports pharmacologic testing.
experimental_model_type: ORGANOID
namo_type: namo:Organoid
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
tissue_term:
preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
conditions:
- autosomal dominant polycystic kidney disease
- PKD1 knockout
- PKD2 knockout
- control kidney tissue
cell_source: Adult human kidney CD24-positive tubular epithelial cells expanded as tubuloids, with CRISPR-edited PKD1 or PKD2 knockout comparators
culture_system: Long-term three-dimensional adult kidney tubuloid culture with single-cell transcriptomic and cyst-size readouts
publication: PMID:36303074
findings:
- statement: Adult kidney tubuloids reconstitute cyst formation and disease-driving transcriptional programs seen in human ADPKD tissue
evidence:
- reference: PMID:36303074
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "We show that kidney tubuloids can be used to model the most common inherited kidney disease, namely autosomal dominant polycystic kidney disease (ADPKD), reconstituting the phenotypic hallmark of this disease with cyst formation."
explanation: Establishes adult kidney tubuloids as a disease-relevant human model that reproduces cyst formation.
- reference: PMID:36303074
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Single-cell RNA sequencing of CRISPR-Cas9 gene-edited PKD1- and PKD2-knockout tubuloids and human ADPKD and control tissue shows similarities in upregulation of disease-driving genes."
explanation: Links the tubuloid phenotype to transcriptional programs observed in human ADPKD tissue.
- statement: This adult epithelial model supports response testing for the clinically used V2-receptor antagonist tolvaptan
evidence:
- reference: PMID:36303074
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Furthermore, in a proof of concept, we demonstrate that tolvaptan, the only approved drug for ADPKD, has a significant effect on cyst size in tubuloids but no effect on a pluripotent stem cell-derived model."
explanation: Provides translational relevance for a model aligned to vasopressin-linked cyst expansion biology.
evidence:
- reference: PMID:36303074
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Long-term-cultured CD24+ cell-derived tubuloids represent a functional human kidney tubule."
explanation: Supports the use of adult human tubuloids as a renal epithelial model system for PKD.
notes: >-
Useful when adult tubular identity or differential tolvaptan response is
the focus, rather than early nephrogenic organoid phenotypes.
- name: ARPKD organoid-on-chip mechanosensing model
description: >-
Perfused human PKHD1-mutant kidney organoids integrated with organ-on-chip
culture introduce flow-dependent biophysical cues missing from static
culture and expose distal-nephron dilation and mechanosensing programs
relevant to ARPKD.
experimental_model_type: ORGAN_ON_CHIP
namo_type: namo:OrganOnChip
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
tissue_term:
preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
cell_types:
- preferred_term: nephron tubule epithelial cell
term:
id: CL:1000494
label: nephron tubule epithelial cell
conditions:
- autosomal recessive polycystic kidney disease
- PKHD1 mutation
- flow culture
- static organoid control
cell_source: Human PKHD1-mutant kidney organoids derived from induced pluripotent stem cells
culture_system: Perfused organoid-on-chip culture comparing flow and static conditions
publication: PMID:36129975
findings:
- statement: Flow-conditioned ARPKD organoid-on-chip cultures reveal distal nephron dilatation not captured by static organoids alone
evidence:
- reference: PMID:36129975
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "PKHD1-mutant organoids-on-a-chip are subjected to flow that induces clinically relevant phenotypes of distal nephron dilatation."
explanation: Supports the role of the chip platform in revealing flow-dependent tubular dilation relevant to ARPKD.
- reference: PMID:36129975
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Transcriptomics discover 229 signal pathways that are not identified by static models."
explanation: Shows that adding biophysical flow changes the mechanistic readout relative to static organoid systems.
- statement: The chip model nominates mechanosensing targets and supports experimental suppression of cyst formation
evidence:
- reference: PMID:36129975
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Mechanosensing molecules, RAC1 and FOS, are identified as potential therapeutic targets and validated by patient kidney samples."
explanation: Grounds the model's mechanistic utility in pathway discovery linked to patient tissue.
- reference: PMID:36129975
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "On the basis of this insight, we tested two U.S. Food and Drug Administration-approved and one investigational new drugs that target RAC1 and FOS in our organoid-on-a-chip model, which suppressed cyst formation."
explanation: Demonstrates utility of the ARPKD chip model for experimental therapeutic testing.
evidence:
- reference: PMID:36129975
supports: SUPPORT
evidence_source: IN_VITRO
snippet: "Here, we unite organoids with organ-on-a-chip technology to unravel disease pathology and develop therapies for autosomal recessive polycystic kidney disease."
explanation: Supports this as a disease-relevant human organoid-on-chip model for ARPKD.
notes: >-
Most directly informs flow-dependent tubular dilation and mechanosensing
rather than the full systemic hepatorenal phenotype of ARPKD.
datasets:
- accession: geo:GSE7869
title: Expression data from renal cysts of autosomal dominant polycystic kidney disease (ADPKD) patients
description: Microarray profiling comparing ADPKD kidney cyst epithelium with non-cystic kidney tissue to identify dysregulated pathways in cyst growth.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: MICROARRAY
sample_types:
- preferred_term: kidney epithelium
tissue_term:
preferred_term: kidney
term:
id: UBERON:0002113
label: kidney
conditions:
- ADPKD cyst epithelium
- non-cystic kidney tissue
publication: PMID:19346236
notes: >-
Public ADPKD microarray dataset frequently used to study cystogenesis-related signaling changes.
evidence:
- reference: PMID:23524344
reference_title: "Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy."
supports: SUPPORT
snippet: "Microarray data are available at GEO website (accession number: GSE7869)."
explanation: Confirms the GEO accession for the ADPKD cyst epithelium microarray dataset.
- reference: PMID:19346236
reference_title: "Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks."
supports: SUPPORT
snippet: "To elucidate the molecular pathways that modulate renal cyst growth in ADPKD, we performed global gene profiling on cysts of different size (<1 ml, n = 5; 10-20 ml, n = 5; >50 ml, n = 3) and minimally cystic tissue (MCT, n = 5) from five PKD1 human polycystic kidneys using Affymetrix HG-U133 Plus 2.0 arrays."
explanation: Describes the PKD1 cyst epithelium microarray experiment underlying GSE7869.
- accession: gtex:GTEx_v8_Kidney_Cortex
title: GTEx v8 kidney cortex bulk RNA-seq
description: Bulk RNA-seq from healthy kidney cortex samples providing control transcriptomes for comparison to ADPKD cystic tissue.
organism:
preferred_term: human
term:
id: NCBITaxon:9606
label: Homo sapiens
data_type: BULK_RNA_SEQ
sample_types:
- preferred_term: kidney cortex
tissue_term:
preferred_term: kidney cortex
term:
id: UBERON:0001225
label: cortex of kidney
publication: PMID:39815096
notes: >-
Healthy kidney reference transcriptomes useful as baseline controls for differential expression analyses in ADPKD studies.
evidence:
- reference: PMID:39815096
reference_title: "The human and non-human primate developmental GTEx projects."
supports: SUPPORT
snippet: "The data will comprise whole-genome sequencing, extensive bulk, single-cell and spatial gene expression profiles, and chromatin accessibility data across tissues and development."
explanation: Establishes dGTEx as a bulk expression resource providing control transcriptomes across tissues including kidney.